論文

査読有り
2011年7月

Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type

LEUKEMIA & LYMPHOMA
  • Daisuke Ennishi
  • ,
  • Yoshinobu Maeda
  • ,
  • Nobuharu Fujii
  • ,
  • Eisei Kondo
  • ,
  • Katsuji Shinagawa
  • ,
  • Kazuma Ikeda
  • ,
  • Koichi Ichimura
  • ,
  • Tadashi Yoshino
  • ,
  • Mitsune Tanimoto

52
7
開始ページ
1255
終了ページ
1261
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3109/10428194.2011.572322
出版者・発行元
INFORMA HEALTHCARE

The prognosis for patients with advanced or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) is extremely poor. Thus, allogeneic stem cell transplantation (allo-HSCT) should be considered for this disease. However, reports of allo-HSCT for ENKL are limited because of the rarity of the disease. Here, we describe the clinical course of 12 cases of advanced and refractory ENKL treated with allo-HSCT, including five cases with cord blood transplant. With a median follow-up of 13 months (range, 1-168 months), seven patients are alive in remission, five have died, and one treatment-related death occurred. All patients with disease progression at transplant died of disease progression, whereas seven of eight patients with a complete or partial response are long-term survivors. Allo-HSCT is a feasible and promising consolidation therapy for advanced and relapsed ENKL. The disease status before allo-HSCT is well associated with general outcome, and thus induction treatment is very important for this disease.

Web of Science ® 被引用回数 : 31

リンク情報
DOI
https://doi.org/10.3109/10428194.2011.572322
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000291992400017&DestApp=WOS_CPL
URL
http://www.scopus.com/inward/record.url?eid=2-s2.0-79959612774&partnerID=MN8TOARS
URL
http://orcid.org/0000-0003-0995-9405

エクスポート
BibTeX RIS